Fabino Life Sciences Ltd
₹ 29.1
-4.99%
19 Apr
- close price
About
Fabino Life Sciences is engaged in manufacturing, marketing, trading, and packing of pharmaceutical and other wellness-focused consumer products[1]
Key Points
- Market Cap ₹ 6.11 Cr.
- Current Price ₹ 29.1
- High / Low ₹ 43.8 / 25.5
- Stock P/E 122
- Book Value ₹ 19.8
- Dividend Yield 0.00 %
- ROCE 0.46 %
- ROE 0.24 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 1.16% over last 3 years.
- Company has high debtors of 275 days.
- Working capital days have increased from 301 days to 443 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|
2.76 | 7.52 | 3.06 | 4.19 | 3.36 | 3.26 | |
2.44 | 7.20 | 2.99 | 4.09 | 3.33 | 3.17 | |
Operating Profit | 0.32 | 0.32 | 0.07 | 0.10 | 0.03 | 0.09 |
OPM % | 11.59% | 4.26% | 2.29% | 2.39% | 0.89% | 2.76% |
0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | |
Interest | 0.29 | 0.20 | 0.01 | 0.01 | 0.01 | 0.00 |
Depreciation | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 |
Profit before tax | 0.00 | 0.10 | 0.04 | 0.07 | 0.01 | 0.06 |
Tax % | 30.00% | 25.00% | 28.57% | 0.00% | ||
0.00 | 0.07 | 0.03 | 0.05 | 0.01 | 0.05 | |
EPS in Rs | 0.00 | 4.67 | 0.25 | 0.24 | 0.05 | 0.24 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -24% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -48% |
TTM: | -55% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -9% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 1% |
Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|
Equity Capital | 0.15 | 0.15 | 1.20 | 2.10 | 2.10 | 2.10 |
Reserves | 0.45 | 0.52 | 0.10 | 2.00 | 2.01 | 2.06 |
2.52 | 1.08 | 0.31 | 0.05 | 0.41 | 0.48 | |
5.43 | 1.83 | 0.65 | 0.48 | 0.50 | 0.66 | |
Total Liabilities | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 5.30 |
0.10 | 0.08 | 0.16 | 0.17 | 0.15 | 0.14 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
8.45 | 3.50 | 2.10 | 4.46 | 4.87 | 5.16 | |
Total Assets | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 5.30 |
Cash Flows
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
0.18 | 2.44 | -0.45 | -1.90 | -0.68 | |
-0.01 | 0.00 | -0.10 | -0.05 | -0.01 | |
-0.18 | -2.37 | 0.45 | 2.47 | 0.34 | |
Net Cash Flow | 0.00 | 0.07 | -0.10 | 0.52 | -0.35 |
Ratios
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Debtor Days | 338.55 | 113.09 | 158.64 | 125.44 | 274.84 |
Inventory Days | 988.71 | 15.36 | 62.61 | 174.83 | 147.24 |
Days Payable | 1,024.81 | 77.34 | 63.94 | 34.76 | 45.78 |
Cash Conversion Cycle | 302.45 | 51.11 | 157.31 | 265.51 | 376.29 |
Working Capital Days | 334.58 | 51.93 | 165.80 | 292.70 | 443.21 |
ROCE % | 12.32% | 2.98% | 2.78% | 0.46% |
Documents
Announcements
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 2d
- Certificate As Per Regulation 40 (9) For The Year Ended March 31, 2024 16 Apr
- Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Period Ended March 31, 2024. 15 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Apr
-
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
2 Apr - Amendment to MOA pursuant to Name Change and Object Change.
Business Area[1] The company's core business is marketing of pharmaceutical formulations & products in India through their own distribution network and sales force under their brand name, getting ayurvedic formulations manufactured through loan licensing facilities, packing, labeling, etc